The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
The fact that it showed anything to your point Dave lifetime exposure is staggering also on patients who are already maximally statin eyes so coming back to this thing about lifetime exposure this is where the Mendelian randomization becomes a very important tool in understanding LDLs causality
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
we have two outcome trials Fourier and odyssey Warrior being in stable ascvd and odyssey and patients with recent acute coronary syndrome that show that they also reduce major adverse cardiovascular events